A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech, Natasha Woodward, Nancy Chan, Joanne Mortimer, Louie Naumovski, Silpa Nuthalapati, Bo Tong, Fang Jiang, Peter Ansell, Christine K. Ratajczak, Jasgit C. Sachdev
Topics & Concepts
ConjugateProlactinAntibody-drug conjugateAntibodyMedicineDrugReceptorPharmacologyInternal medicineCancer researchOncologyImmunologyMonoclonal antibodyHormoneMathematicsMathematical analysisNeuroblastoma Research and TreatmentsCancer, Hypoxia, and MetabolismGrowth Hormone and Insulin-like Growth Factors